Compound class:
Synthetic organic
Comment: KSP-1007 is a bicyclic boronic acid β-lactamase inhibitor (BLI), with broad-spectrum activity against both serine and metallo-β-lactamases, discovered through a collaboration between the Kitasato Institute (Tokyo, Japan) and Sumitomo Pharma (Osaka, Japan) [1]. KSP-1007, in combination with meropenem, is under clinical development for the treatment of infections caused by carbapenem-resistant bacterial infections.
|
|
References |
1. Takemoto K, Nakayama R, Fujimoto K, Suzuki Y, Takarabe Y, Honsho M, Kitahara S, Noguchi Y, Matsui H, Hirose T et al.. (2024)
In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-β-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother,: e0160223 [Epub ahead of print]. [PMID:38709005] |